Electromed, Inc.
AMEX:ELMDMedical - Devices
+$0.43 today
- Market cap
- $190.13M
- Beta
- 0.52
- P/E (TTM)
- 30.5
- EPS (TTM)
- $1.23
Volume 0.05M
Average 0.06M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Electromed, Inc.
AMEX:ELMD
Intrinsic Alpha fair value
Locked
Current Price
$23.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +49.0% | +6.0% (5yr)1 analysts |
| Revenue | N/A | N/A | +15.4% | +6.0% (5yr)1 analysts |
| Net Income | N/A | N/A | +48.4% | +5.8% (5yr)1 analysts |
| EBIT | N/A | N/A | +49.2% | +5.9% (5yr)1 analysts |
Analysis
Recent growth has been strongest in EBIT at +49.2% over three years. Forward estimates point to Revenue at +6.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
ResMed Inc. NYSE:RMD | $33.69B | $239.53 | Undervalued | 18.1 | -2.37% |
AdaptHealth Corp. NASDAQ:AHCO | $1.05B | $7.66 | Undervalued | -16.3 | -20.42% |
Tactile Systems Technology, Inc. NASDAQ:TCMD | $600.58M | $26.81 | Overvalued | 29.1 | +8.61% |
Viemed Healthcare, Inc. NASDAQ:VMD | $347.48M | $9.17 | Undervalued | 27.4 | +35.59% |
Pulmonx Corporation NASDAQ:LUNG | $124.55M | $2.86 | Not rated | -1.0 | +109.16% |
Continue the stock analysis
Jump to another research area for this company.